Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207931 · ClinicalTrials.gov registry record · Phase 4
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
A Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT04207931: Recruiting Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA), sponsored by Wake Forest University Health Sciences.
NCT04207931 is a Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 250 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04207931, a Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups
Primary Outcome
Photographs of the subject's scalp will be taken at baseline. This instrument is a 6-point scale that includes gradations in hair loss from normal (0) to bald scalp (5). Higher numbers denote greater hair loss.
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Minoxidil
- DRUG Topical steroid class I-II
- DRUG Doxycyline
Study Locations (1)
North Carolina
- Wake Forest Baptist Health Department of Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What NCT04207931 shows while recruiting
NCT04207931 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Central Centrifugal Cicatricial Alopecia (CCCA) appearing as the primary indexed condition, and to 4 interventions - of which Triamcinolone Acetonide is the first listed.
NCT04207931 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04207931 about?
NCT04207931 is a clinical study titled "Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study". The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups
What is the current status of trial NCT04207931?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2018-04-30. Estimated completion is 2026-08.
What conditions does trial NCT04207931 study?
This clinical trial studies the following conditions: Central Centrifugal Cicatricial Alopecia (CCCA).
What interventions are being tested in trial NCT04207931?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Minoxidil (DRUG), Topical steroid class I-II (DRUG), Doxycyline (DRUG).
Who is sponsoring clinical trial NCT04207931?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04207931 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04207931's enrollment target sits among peer trials
250 342nd of 2000 higher than 1,649 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI